Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma

Archives of Ophthalmology

Volumn 127, Issue 8, 2009, Pages 1043-1047

  Kang, Shin J ^a   Durairaj, Chandrasekar ^b   Kompella, Uday B ^b   O'Brien, Joan M ^c   Grossniklaus, Hans E ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RETINA TUMOR; RETINOBLASTOMA; SINGLE DRUG DOSE; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CARBOPLATIN; CONJUNCTIVA; DENDRIMERS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INJECTIONS; MICE; MICE, TRANSGENIC; NANOPARTICLES; RETINAL NEOPLASMS; RETINOBLASTOMA; TREATMENT OUTCOME;

EID: 68549123611     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.185     Document Type: Article

References (26)

1. Young JL, Smith MA, Roffers SD, Liff JM, Bunin GR. Retinoblastoma. In: Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999. NIH publication 99-4649. http://seer.cancer.gov/publications/childhood. Accessed January 12, 2009.
2. Shields JA, Shields CL. Current management of retinoblastoma. Mayo Clin Proc. 1994;69(1):50-56.
3. Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene. 2006;25(38):5341-5349.
4. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121-1128.
5. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267.
6. Pradhan DG, Sandridge AL, Mullaney P, et al. Radiation therapy for retinoblastoma: a retrospective review of 120 patients. Int J Radiat Oncol Biol Phys. 1997;39(1):3-13.
7. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105(4):573-579, discussion 579-580.
8. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118(4):577-578.
9. Murray TG, Cicciarelli N, O'Brien JM, et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol. 1997;115(10):1286-1290.
10. Hayden BH, Murray TG, Scott IU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol. 2000;118(11):1549-1554.
11. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947-1950.
12. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120-1124.
13. Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142(2):310-315.
14. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. 2005;112(6):1151-1158.
15. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.
16. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans. 2007;35(pt 1):61-67.
17. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials. 2007;28(3):504-512.
18. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343(6259):665-669.
19. ImageJ [computer program]. Version 1.41. Bethesda, MD: National Institutes of Heath; 2008.
20. Valière C, Arnaud P, Caroff E, Duaphin JF, Clément G, Brion F. Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion. Int J Pharm. 1996;138(1):125-128.
21. Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target. 2007;15(3):163-183.
22. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008;14:150-160.
23. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57(12):1555-1563.
24. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev. 2005;57(15):2271-2286.
25. Tsui JY, Dalgard C, Van Quill KR, et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49(2):490-496.
26. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21(10):1797-1804.